Hepatitis in Medical News

Surveyed Physicians Will Treat Over 50 Percent of Hepatitis C Genotype 1-Infected Patients With the Protease Inhibitor Telaprevir

WALTHAM, Mass., Aug. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on profiles provided to them of emerging protease inhibitors, surveyed physicians indicate that they will prescr...

Top Hepatitis C Treatments Equally Effective

Landmark assessment also finds treating early helps prevent liver failure WEDNESDAY, July 22 (HealthDay News) -- A landmark hepatitis C virus study shows that the top two treatment options are equally effective and safe. The long-awaited study, thought to be the largest of its kind...

Mass. General-based research center will investigate why immune system fails to control hepatitis C

A research consortium based at Massachusetts General Hospital (MGH) has been awarded $15 million from the National Institute of Allergy and Infectious Diseases to investigate how the hepatitis C virus (HCV) resists suppression and clearance by the immune system. The five-year grant will support a...

New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report

NEW YORK, July 7 /PRNewswire/ -- Reportlinker.com just added a new market research report to its catalogue. World Hepatitis C Virus And Therapeutics Market http://www.reportlinker.com/p0119497/World-Hepatitis-C-Virus-And-Therapeutics-Market.html?utm_source=PRNWire&utm_medium=...

Pharmasset Nominates PSI-938 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development

PRINCETON, N.J., July 7 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) announced today the nomination of PSI-352938 ("PSI-938") as a lead development candidate from two series of purine analogs for the treatment of chronic hepatitis C virus (HCV) infection. PSI-938 is a proprietary n...

JNCI news brief: Hepatitis B virus mutations may predict risk of liver cancer

Certain mutations in the DNA of the hepatitis B virus (HBV) are associated with the development of liver cancer and may help predict which patients with HBV infections are at increased risk of the disease, according to a large meta-analysis in the Journal of the National Cancer Institute , publis...

Good news for some hard-to-treat hepatitis C patients

ST. LOUIS In a multi-center trial led by a Saint Louis University researcher, investigators found that a new combination therapy of daily consensus interferon and ribavirin helps some hepatitis C patients who have not responded to previous treatment. The findings, published in the June issue of ...

Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients

- PSI-7851 was generally safe and well tolerated in Phase 1a single ascending dose trial - Further results from single ascending and multiple ascending dose trials are expected in second half 2009 PRINCETON, N.J., June 9 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) annou...

NEJM study points to new era in hepatitis C treatment

NEW YORK (June 4, 2009) -- For patients with the most common form of hepatitis C, the addition of a hepatitis Cspecific protease inhibitor called telaprevir to the current standard therapy can significantly improve the chances of being cured, and it does it in half the time of standard therapy alo...

Resource for Those Living with Hepatitis C Announces Website Redesign

Hepatitis-Central.com, a longstanding support resource for those afflicted with Hepatitis C and their physicians, caregivers and families, has been redesigned. New features include video clips, podcasts, social networking tools and updates on this virus. (PRWEB) June 2,...

New treatment option for patients with chronic hepatitis C

A new combination therapy of daily consensus interferon (CIFN) and ribavirin is effective for some people with chronic hepatitis C (HCV) who do not respond to standard therapy. The treatment works particularly well in interferon-sensitive patients who have lower fibrosis scores, according to a new...

National Viral Hepatitis Roundtable Observes World Hepatitis Day and Calls for Increased Federal Action

Greater Investments Public Health a Must Federal Leadership Needed to Focus Policy Actions at the Federal Level (PRWEB) - Today, on the second annual World Hepatitis Day , more than 200 viral hepatitis groups around the world have planned observances to raise global aw...

National Viral Hepatitis Roundtable Observes World Hepatitis Day and Calls for Increased Federal Action

Greater Investments in Public Health a Must Federal Leadership Needed to Focus Policy Actions at the Federal Level WASHINGTON, May 19 /PRNewswire/ -- Today, on the second annual World Hepatitis Day, more than 200 viral hepatitis groups around the world have planned observances to raise...

ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference

FREDERICK, Md., May 14 /PRNewswire/ -- ImQuest Bio and Arisyn jointly presented important new results on ATI-0810 (Formerly PG301029), a novel late stage inhibitor of hepatitis C virus (HCV) replication, at the 13th ISVHLD meeting held last week in Washington D.C. The presentation highlighted t...

New Treatment Combo Better Against Hepatitis C

Adding antiviral telaprevir increases cure rate, studies show,,,, WEDNESDAY, April 29 (HealthDay News) -- Adding the antiviral drug telaprevir to standard treatment for hepatitis C increases the cure rate, two new studies show. Current treatment for hepatitis C (HCV) genotype 1, the...

First evidence for DNA-based vaccination against chronic hepatitis C

Copenhagen, Denmark, Thursday 23 April: The first-proof-of-concept for a DNA-based therapeutic vaccination against chronic hepatitis C was announced today at EASL 2009, the Annual Meeting of the European Association for the Study of the Liver in Copenhagen, Denmark. In the first clinical trial ...

Diabetes, obesity and hypertension increase mortality in hepatitis C patients

Copenhagen, Denmark, Wednesday 22nd April: The specific impact of metabolic syndrome on mortality in hepatitis C patients has been revealed by new research to be presented on Sunday April 26 at EASL 2009, the Annual Meeting of the European Association for the Study of the Liver in Copenhagen, Den...

PRA SPEAKING EVENT: Phase I Studies with Hepatitis C Compounds in Healthy Volunteers and Patients: Views from Inside

RALEIGH, N.C., April 8 /PRNewswire/ -- PRA International, a leading Clinical Research Organization, announces Dr. Andre van Vliet, Vice President of Medical Affairs - Early Development Services (EDS), will host an audio conference on the development of New Chemical Entities (NCEs) in the treatment...

Hard To Treat Diseases (HTDS) Offers Hepatitis A Vaccine in India

SHENZHEN, China, April 3 /PRNewswire-FirstCall/ - Hard To Treat Diseases (HTDS) www.htdsmedical.com is pleased to announce that its China based operating subsidiary Mellow Hope has surpassed sales of 200,000 units of Hepatitis A Vaccine in India. The Hepatitis A Vaccine (BIOVAC-A) was first la...

New studies examine elimination of hepatitis B and C

Two new studies in the April issue of Hepatology explore the ways that hepatitis B virus (HBV) and hepatitis C virus (HCV) can be cleared from patients' bodies. Hepatology is a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD)....

The immune system's role in hepatitis C recurrence after liver transplantation

A new study pinpoints certain aspects of the immune system that may play a role in the recurrence and progression of hepatitis C virus (HCV) after liver transplantation. The study is in the April issue of Liver Transplantation , a journal published by John Wiley & Sons. The article is also availa...

2-day results predict ultimate response to therapy in chronic hepatitis C

A new study suggests that previously noted low rates of successful hepatitis C virus (HCV) therapy in African Americans are in large part due to very early differences in the antiviral activity induced by interferon. The study is published in the April 15 issue of the Journal of Infectious Disea...

Progress Reported Against Gene Involved in Hepatitis C

Finding could lead to new treatments for the disease, researchers say,,,, WEDNESDAY, March 18 (HealthDay News) -- Nearly 100 genes that support replication of the hepatitis C virus (HCV) in the human body have been identified by Massachusetts General Hospital researchers. They also...

In Hepatitis C Virus Treatment, Interviewed Experts Indicate That Telaprevir- and Boceprevir-Based Regimens Have Advantages Over Pegasys/Ribavirin in Sustained Virologic Response

Telaprevir in Combination with a Long-Acting Interferon and Ribavirin Will Earn Decision Resources' Clinical Gold Standard for Hepatitis C Virus in 2012, According to a New Report from Decision Resources WALTHAM, Mass., March 18 /PRNewswire/ -- Decision Resources, one of the world's leading r...

Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology

Editorial Accompanies Manuscript in March Issue TAMPA, Fla., March 2 /PRNewswire/ -- A study evaluating nitazoxanide in combination with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus (HCV) infection with genotype 4 was published in the March issue of Gastroen...

Liver transplant recipients with hepatitis B may need lifelong antiviral treatment

Patients who undergo liver transplantation for hepatitis B-related liver damage should receive lifelong antiviral treatment to keep the disease from coming back. A new study shows that they lack cellular immunity against the disease, making recurrence likely if antiviral treatment is withdrawn. Th...

Pitt receives $11 million from NIH to coordinate hepatitis B clinical research network

PITTSBURGH, Jan. 29 The National Institute of Diabetes and Digestive and Kidney Diseases has awarded a seven-year $11 million grant to the University of Pittsburgh Graduate School of Public Health to coordinate the Hepatitis B Clinical Research Network a consortium of 15 clinical and research ce...

PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine

- Largest Prospective Study Demonstrates Treatment Success, and Highlights Potential Factors that Affect Health Outcomes, in Latino Population Suffering from Chronic Hepatitis C - NUTLEY, N.J., Jan. 14 /PRNewswire/ -- Results from the LATINO study, the largest study conducted to-date in Lat...

Hispanics Respond Poorly to Standard Hepatitis C Therapy

They and blacks still share outcome disparities in treatment of liver disease, study says WEDNESDAY, Jan. 14 (HealthDay News) -- The standard treatment for hepatitis C does not appear to help Hispanic whites with the liver disease as much as it helps non-Hispanic whites, a new study su...

May hepatic granulomas be part of the histological spectrum of chronic hepatitis C?

While older large series of patients with hepatic granulomas have found sarcoidosis and tuberculosis to be the most common causes of hepatic granulomas, recent works have noted some patients with chronic hepatic C and hepatic granulomas and no other obvious associations. Today, patients that under...

Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C

First and only approved peginterferon in combination with ribavirin for previously untreated children with chronic hepatitis C addresses unmet medical need KENILWORTH, N.J., Dec. 12 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today announced that the U.S. Food and...

Improved Testing for Hepatitis B Virus From Roche

PLEASANTON, Calif., Dec. 8 /PRNewswire/ -- Roche Molecular Diagnostics announced today that it has received CE Mark certification for its new COBAS(R) AmpliPrep / COBAS(R) TaqMan(R) HBV Test v2.0, allowing it to be sold for clinical use in the European Union. This highly sensitive test offers Roc...

HALT-C researchers: Interferon as long-term treatment for hepatitis C not effective

DALLAS Dec. 4, 2008 Use of the drug interferon as a long-term maintenance strategy to slow the progression of liver disease associated with the hepatitis C virus is ineffective, UT Southwestern Medical Center researchers and their colleagues from nine other institutions have found in a multicent...

Hepatitis C Therapeutic DNA Vaccine Delivered by Inovio Biomedical's Electroporation Technology Reduces Viral Load by Up to 99.7% : Clinical Data Presented at Annual Scientific Meeting of the American Association for the Study of Liver Diseases

Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that its partner, Tripep AB, reported positive additional interim results from its ongoing phase I/II clinical study of its therapeutic DNA vacc...

Tibotec presents interim findings for TMC435, an investigational genotype 1 hepatitis C treatment

SAN FRANCISCO (November 3, 2008) New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection. Tibotec will present findings from three TMC435 studies, including a lat...

Roche Receives FDA Approval for Hepatitis C Viral Load Test on Its Fully Automated Real-Time PCR Platform

Improved laboratory efficiencies and standardization to personalize patient care PLEASANTON, Calif., Oct. 30 /PRNewswire/ -- Roche Molecular Diagnostics today announced that the U.S. Food & Drug Administration (FDA) has approved the COBAS(R) AmpliPrep / COBAS(R) ...

Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study

SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced today that it has initiated dosing ANA598 in patients chronically infected with hepatitis C virus (HCV) in a Phase Ib study. ANA598 is an investigational, oral, non-nucleoside polymerase inhibi...

Why Are Some Veterans Who Are Coinfected With Hepatitis C and HIV More Likely to Be Treated for HCV Than Others?

Research to be presented Sunday, November 2, 2008 at this year's liver meeting in San Francisco, California, October 31 - November 4 SAN FRANCISCO, Oct. 28 /PRNewswire/ -- Researchers from the Michael E. DeBakey VA Medical Center, led by Jennifer Kramer, Ph.D., looked at a population of U...

Existing anti-obesity drugs may be effective against flu, hepatitis and HIV

Viruses dramatically increase cellular metabolism, and existing anti-obesity drugs may represent a new way to block these metabolic changes and inhibit viral infection, according to a study published today in the journal Nature Biotechnology . Metabolism refers to all the reactions by which ...

Majority of children vaccinated against hepatitis B not at increased risk of MS

ST. PAUL, Minn. The majority of children vaccinated against hepatitis B are not at an increased risk of developing multiple sclerosis (MS), according to a study to be published in the October 8, 2008, online issue of Neurology , the medical journal of the American Academy of Neurology. The s...